A drug used to treat advanced breast cancer has had what appears to be unprecedented success in prolonging lives in a clinical trial, researchers reported on Sunday.
Patients who received the drug — Perjeta, from the Swiss drug maker Roche — had a median survival time nearly 16 months longer than those in the control group.
{iframe}http://www.nytimes.com/2014/09/29/business/roche-breast-cancer-drug-appears-to-greatly-extend-patients-lives.html?_r=0{/iframe}